According to the SEC Form 4 filings, Amado Rafael, being in a position of
The largest sale of all time was on 2020-10-07 and amounted to 16538 shares of Allogene Therapeutics, Inc. for $651,515.
No biography is available at this moment.
| 2024-08-12 | Sale | Zai Lab Limited ZLAB | See Remarks | 3,115 0.0031% | $16.20 | $50,463 | +60.88% | |
| 2024-04-04 | Sale | Zai Lab Limited ZLAB | See Remarks | 1,952 0.002% | $15.67 | $30,594 | +29% | |
| 2024-03-15 | Sale | Zai Lab Limited ZLAB | See Remarks | 2,544 0.0026% | $18.86 | $47,980 | +5.5% | |
| 2024-01-02 | Sale | Zai Lab Limited ZLAB | See Remarks | 19,363 0.0199% | $26.30 | $509,169 | -23.5% | |
| 2022-08-02 | Sale | Allogene Therapeutics, Inc. ALLO | EVP of R&D and CMO | 2,000 0.0013% | $11.97 | $23,940 | -47.84% | |
| 2022-07-05 | Sale | Allogene Therapeutics, Inc. ALLO | EVP of R&D and CMO | 2,000 0.0014% | $11.44 | $22,880 | -38.52% | |
| 2022-06-21 | Sale | Allogene Therapeutics, Inc. ALLO | EVP of R&D and CMO | 2,000 0.0014% | $11.18 | $22,360 | -30.17% | |
| 2022-05-19 | Sale | Allogene Therapeutics, Inc. ALLO | EVP of R&D and CMO | 11,500 0.0079% | $7.40 | $85,092 | +18.54% | |
| 2022-03-15 | Sale | Allogene Therapeutics, Inc. ALLO | EVP of R&D and CMO | 5,169 0.0036% | $7.71 | $39,848 | +21.54% | |
| 2021-10-01 | Sale | Allogene Therapeutics, Inc. ALLO | EVP of R&D and CMO | 11,507 0.0084% | $24.35 | $280,185 | -51.55% | |
| 2021-03-15 | Sale | Allogene Therapeutics, Inc. ALLO | EVP of R&D and CMO | 2,798 0.0021% | $38.05 | $106,471 | -42.72% | |
| 2020-10-07 | Sale | Allogene Therapeutics, Inc. ALLO | EVP of R&D and CMO | 16,538 0.0123% | $39.40 | $651,515 | -30.6% | |
| 2020-10-01 | Sale | Allogene Therapeutics, Inc. ALLO | EVP of R&D and CMO | 9,752 0.0073% | $36.37 | $354,662 | -23.71% | |
| 2019-08-06 | Sale | Adaptimmune Therapeutics plc ADAP | President, R&D | 22,086 0.0206% | $2.06 | $45,497 | +36.34% | |
| 2019-01-14 | Sale | Adaptimmune Therapeutics plc ADAP | President, R & D | 6,056 0.0058% | $5.37 | $32,517 | -35.9% |